ArticleBMC musculoskeletal disorders2026
Clinical features and prognostic factors for spinal metastasis from sarcomatoid carcinoma: identifying candidates suitable for surgical intervention.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSarcomatoid carcinoma (SC) frequently metastasizes, with bone being the most common site, and the spine is often affected. However, dedicated studies on spinal metastasis from SC remain scarce, complicating the determination of appropriate surgical intervention strategies.
methodsWe retrospectively analyzed 25 patients with spinal metastasis from SC. Clinical, radiological, pathological, treatment, and survival data were comprehensively evaluated. Prognostic factors were assessed using Kaplan-Meier analysis and Cox regression models, leading to the development of a simplified prognostic stratification system.
resultsAmong the 25 patients, 7 had lung-derived SC and 12 had SC of unknown primary origin. No significant prognostic differences were observed across different primary sites. Notably, 19 patients initially presented with symptoms attributable to spinal metastasis. SC spinal metastases lacked distinct characteristic imaging features. Among treatment modalities, only targeted therapy and immunotherapy demonstrated a trend toward improved survival outcomes. Multivariate analysis identified the number of metastatic lesions, D-dimer level, and neutrophil-to-lymphocyte ratio (NLR) as independent prognostic factors for overall survival (OS). A nomogram constructed from these three factors reliably predicted the 1-year survival rate. We further established a simplified prognostic stratification system that may assist in guiding surgical decision-making.
conclusionTargeted therapy and immunotherapy may confer survival benefits to patients with spinal metastasis from SC. Our prognostic stratification system, based on the number of metastatic lesions, D-dimer level, and NLR, enables estimation of OS and may facilitate risk-adapted surgical stratification, which may serve as a supplement to the present clinical frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.